Today's Updates
Here's some of what is coming soon to NeurologyLive® this week.
Allison B. Reiss, MD, associate professor of medicine at NYU Grossman Long Island School of Medicine discussed the often-overlooked early signs of early-onset Alzheimer disease.
Gefurulimab (Klygefa), a once-weekly, self-administered complement C5 inhibitor from Alexion and AstraZeneca, is now approved in the US for adults with AChR-antibody-positive generalized myasthenia gravis.
A new FDA filing seeks to expand cenobamate's epilepsy indication to primary generalized tonic-clonic seizures, based on positive phase 3 trial data.
The professor of neurology at UT Southwestern Medical Center discussed emerging trials, proposed changes to myelitis diagnostic criteria and nomenclature, and the unmet needs raised by patients at this year’s symposium.
A new global phase 2 trial, TARBELA-AD, will test RG6434, Roche's investigational oral NLRP3 inflammasome inhibitor, in adults with early symptomatic Alzheimer disease.
A pivotal phase 2/3 trial of Zhimeng Biopharma's CB03-154, an oral KCNQ2/3 potassium channel opener, has completed enrollment in amyotrophic lateral sclerosis.
Evan Dellon, MD, discusses phase 3 CROSSING data in which tezepelumab improved histology, dysphagia, and endoscopic findings vs placebo in EoE.
Aasma Shaukat, MD, MPH, discusses an updated SimpleScreen CRC blood test with 18.2% sensitivity for advanced precancerous lesions, up from 13.7%.
Oncology
A scientific review of fluorescence-lifetime imaging as an adjunct for distinguishing residual tumor from treatment-altered fibrosis during cancer surgery.
A clinical review of rehabilitation, psychosocial care, and evidence-informed strategies that support social reintegration and self-confidence after head and neck cancer treatment.
A clinical review of immune editing, tumor evolution, immune escape, biomarkers, treatment resistance, and emerging immunotherapy strategies.
A professional review of targeted protein degraders, including PROTACs, in hormone-driven breast and prostate cancers, with mechanisms, evidence, risks, and clinical implications.
Dr. Harish P and 1 more
Dr. Vijay Agarwal and 1 more
Dr Suvir Singh
Dr Vijay Agarwal and 1 more
Dr. Todd Bauer and 1 more
Dr. Poonam Patil and 1 more
Fastest Growing Medical Platform for Doctors
Address : Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone : +1-415-463-3094
Email : anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
To get started please enter your email ID
By entering your details you agree to our
Please check your email for the four-digit security code and enter it below.
Didn't receive a code? Resend OTP
Join to enhance your clinical skills and gain specialized in-depth medical knowledge
Country
State
64824 This Month
2524 Today